Clinical Trial Update: Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for EXL01, a live biotherapeutic product intended to prevent recurrence of Clostridioides difficile infection in high-risk patients, cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• EXL01

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Clostridioides Difficile Infection, Recurrent Infection | Phase 1, Phase 2 | Status: RECRUITING